Hepatic metastases from an unknown primary neoplasm (UPN): Survival, prognostic indicators and value of extensive investigations

被引:23
|
作者
Hogan, BA
Thornton, FJ
Brannigan, M
Browne, TJ
Pender, S
O'Kelly, P
Lyon, SM
Lee, MJ
机构
[1] Beaumont Hosp, Dept Radiol, Dublin 9, Ireland
[2] Beaumont Hosp, Dept Pathol, Dublin 9, Ireland
[3] Royal Coll Surgeons Ireland, Sch Med, Dublin 2, Ireland
关键词
unknown primary neoplasm; hepatic metastases; liver biopsy;
D O I
10.1053/crad.2002.1085
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
AIM: The objectives of this study were to identify prognostic features for patients with hepatic metastases and unknown primary neoplasms (UPN), determine the common primary tumours, assess the value of diagnostic tests in finding these tumours, and evaluate the impact of therapy and knowledge of the primary tumour on patient survival. MATERIALS AND METHODS: Eighty-eight patients with UPN and liver biopsy proven hepatic metastases over a 10-year period were reviewed (M:F, 58:30; age range 27-91 years, median 64.5 years). Histopathology, diagnostic investigations and success at identifying the primary neoplasm were recorded. In addition, in 70 patients with adenocarcinoma histology (M:F, 48:22; age range 27-91 years, median 65 years), treatment and survival data from the date of biopsy were recorded. RESULTS: The histological spectrum included adenocarcinoma in 70, neuroendocrine in four, squamous cell carcinoma in four, small cell carcinoma in four, carcinoid in two, hepatoma in one and three others. Extensive investigation identified a primary neoplasm in 16/88 patients (18%) including colorectal in six, gastric in two, lung in four, oesophageal in two, prostate in one and carcinoid in one. In the adenocarcinoma group survival data were available for 62/70 patients. Sixteen of 62 patients received active treatment with either surgery, chemotherapy, radiotherapy or a combination protocol. Forty-six of 62 patients received palliative care alone. Median survival for the adenocarcinoma group overall was 49 days. The median survival for treated patients (49 days) versus untreated patients (52 days) was not significantly different (P = 0.128). Patients < 65 years were more likely to receive active treatment than those > 65 years (P = 0.006). Age with a hazard ratio (HR) of 1.01 (P = 0.178), active treatment (HR = 0.65; P = 0.194), knowledge of the primary neoplasm (HR = 0.60; P = 0.213) and male gender (HR = 0.88; P = 0.642) had no significant effect on survival. CONCLUSION: Although hepatic metastases are associated with poor prognosis, it is essential that a liver biopsy.. be-performed to obtain a histological diagnosis. Adenocarcinoma metastases carry a dismal prognosis, and no prognostic factors, including knowledge of the primary tumour, are significant for patient survival. Extensive investigation is not warranted in patients with adenocarcinoma liver metastases.
引用
收藏
页码:1073 / 1077
页数:5
相关论文
共 35 条
  • [1] Survival benefit of extensive hepatic cytoreduction for symptomatic metastases from neuroendocrine tumors
    Amersi, FF
    Garza, AM
    Ahmad, A
    Bilchik, AJ
    ANNALS OF SURGICAL ONCOLOGY, 2006, 13 (02) : 14 - 14
  • [2] Survival outcomes following craniotomy for intracranial metastases from an unknown primary
    Melissa Gough
    Molly Nielsen
    Ian C. Coulter
    Damian Holliman
    International Journal of Clinical Oncology, 2020, 25 : 1475 - 1482
  • [3] Survival outcomes following craniotomy for intracranial metastases from an unknown primary
    Gough, Melissa
    Nielsen, Molly
    Coulter, Ian C.
    Holliman, Damian
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2020, 25 (08) : 1475 - 1482
  • [4] Prognostic factors and survival in patients with squamous cell carcinoma lymph nodes metastases from an unknown primary to the head and neck
    Zhuang, Shi-Min
    Zhang, Ji
    Chen, Shu-Wei
    Li, Huan
    Song, Ming
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2016, 9 (03): : 5828 - 5834
  • [5] Retrospective Analysis of Survival in Patients with Brain Metastases from an Unknown Primary Tumor
    Cirak, Musa
    Guclu, Dogan Gucluhan
    Akar, Emre
    Kazanci, Mehmet Hanifi
    Tural, Deniz
    TURKISH NEUROSURGERY, 2020, 30 (06) : 932 - 936
  • [6] Survival after lymphadenectomy of nodal metastases from melanoma of unknown primary site
    Gullestad, Hans Petter
    Ryder, Truls
    Goscinski, Mariusz
    JOURNAL OF PLASTIC SURGERY AND HAND SURGERY, 2023, 57 (1-6) : 109 - 114
  • [7] Diagnostic improvement of 111In-pentetreotide scintigraphy in patients with metastases from unknown primary neuroeuroendocrine neoplasm
    Chiti, A
    Savelli, GB
    Bombardieri, E
    RADIOLOGY, 2002, 225 : 520 - 520
  • [8] Hepatic metastases from carcinomas of unknown primary site - Experience of the Montpellier Cancer Center
    Pouessel, D
    Thezenas, S
    Culine, S
    Becht, C
    Senesse, P
    Ychou, M
    GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE, 2005, 29 (12): : 1224 - 1232
  • [9] Prognostic factors among patients with brain metastases from cancer of unknown primary site
    Padilla, C. Simoes
    Ho, V. K. Y.
    van der Strate, I. H.
    Leenders, W. P. J.
    de Vos, F. Y. F. L.
    van Zanten, S. E. M. Veldhuijzen
    Loef, C.
    JOURNAL OF NEURO-ONCOLOGY, 2022, 159 (03) : 647 - 655
  • [10] Prognostic factors among patients with brain metastases from cancer of unknown primary site
    C. Simões Padilla
    V. K. Y. Ho
    I. H. van der Strate
    W. P. J. Leenders
    F. Y. F. L. de Vos
    S. E. M. Veldhuijzen van Zanten
    C. Loef
    Journal of Neuro-Oncology, 2022, 159 : 647 - 655